Orakl Oncology raised US$34 million in a Series A round co-led by Norrsken VC and Singular. The round brings the company's total funding to US$50 million. Orakl builds virtual cancer patients to help drug developers predict whether oncology treatments will work.
Backers and contracts
The oversubscribed round includes InfraVia, the Patient Autonome Fund managed by Bpifrance, Serena, Teampact Ventures, and Plug and Play. Existing investors Verve Ventures, Speedinvest, and HCVC also took part. The company has signed three contracts with pharmaceutical partners.
Company background
Orakl was founded in 2023 as a spin-out of Gustave Roussy, a leading European cancer research institute. The leadership includes CEO Dr Fanny Jaulin, CTO Dr Gustave Ronteix, and COO Dr Diane-Laure Pagès. The company has a team of more than 40 people, 30% of whom hold PhDs.
How the platform works
Orakl pairs patient tumors grown in the lab with clinical histories and deep biological data. It tests potential treatments against these models at scale. The company reports 90% accuracy in predicting cancer clinical trial outcomes.
The new capital will support dataset expansion and a fivefold increase in data generation. Orakl plans to move beyond colorectal and pancreatic cancers into lung and gastric cancers. It will also establish teams in the US and UK to deploy predictions across more than 10 drug programs.